Currently, tazemetostat is being tested in phase 2 trials as monotherapy in NHL, relapsed or refractory INI1-negative tumours or synovial sarcoma, mesothelioma, in combination with the standard of care regimen R-CHOP and with the PD-L1 antibody atezolizumab in NHL and in a phase 1 paediatric study in relapsed or refractory INI1-negative tumours or synovial sarcoma (table 2). This evidence concerns the gene SMARCB1 and non-Hodgkin lymphoma.